Combined oral prolonged-release oxycodone and naloxone in chronic pain management

Bibliography

• Breivik H, Collett B, Ventafridda V, Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333
   PubMed Web of Science ®Google Scholar
• Holzer P, Ahmedzai SH, Niederle N, Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag 2009;5:145-51
   PubMedGoogle Scholar
• Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61:1181-7
   PubMed Web of Science ®Google Scholar
• Mercadante S. Emerging drugs for cancer-related pain. Support Care Cancer 2011;19:1887-93
   PubMed Web of Science ®Google Scholar
• Meissner W, Schmidt U, Hartmann M, Oral naloxone reverses opioid-associated constipation. Pain 2000;84:105-9
   PubMed Web of Science ®Google Scholar
• Smith K, Hopp M, Mundin G, Single and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist-antagonist prolonged-release combination in healthy adult volunteers. ClinTher 2008;30:2051-68
   Google Scholar
• Smith K, Hopp M, Mundin G, Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs 2011;20:427-39
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, A randomized controlled study with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64
   PubMed Web of Science ®Google Scholar
• Nadstawek J, Leyendecker P, Hopp M, Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract 2008;62:1159-67
   PubMed Web of Science ®Google Scholar
• Riley J, Eisenberg E, Muller-Schwefe G, Oxycodone: a review of its use in the management of pain. Curr Med Res Opin 2008;24:175-92
   PubMed Web of Science ®Google Scholar
• Van Dorp EL, Yassen A, Dahan A. Naloxone treatment in opioidaddiction: the risks and benefits. Expert Opin Drug Saf 2007;6:125-32
   PubMed Web of Science ®Google Scholar
• Lalovic B, Phillips B, Risler LL, Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004;32:447-54
   PubMed Web of Science ®Google Scholar
• Smith K, Hopp M, Mundin G, Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012;50:360-7
   PubMed Web of Science ®Google Scholar
• Vondrackova D, Leyendecker P, Meissner W, Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54
   PubMed Web of Science ®Google Scholar
• Simpson K, Leyendecker P, Hopp M, Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008;24:3503-12
   PubMed Web of Science ®Google Scholar
• Löwenstein O, Leyendecker P, Hopp M, Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10:531-43
   PubMed Web of Science ®Google Scholar
• Ahmedzai SH, Nauck F, Bar-Sela G, A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Pall Med 2012;26:50-60
   PubMed Web of Science ®Google Scholar
• Löwenstein O, Leyendecker P, Lux EA, Efficacy and safety of combined prolonged release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010;10:12
   PubMedGoogle Scholar
• Schutter U, Frunert S, Meyer C, Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin 2010;26:1377-87
   PubMed Web of Science ®Google Scholar
• Hermanns K, Junker U, Nolte T. Prolonged-release oxycodone-naloxone in the treatment of neuropathic pain – results from a large observational study. Expert Opin Pharmacother 2012;13:299-311
   PubMed Web of Science ®Google Scholar
• Sandner-Kiesling A, Leydendecker F, Hopp M, Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010;64:763-74
   PubMed Web of Science ®Google Scholar
• Clemens KE, Quednau I, Klaschik E. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer. Int J Clin Pract 2011;65:472-8
   PubMed Web of Science ®Google Scholar
• Ricerca IMS Health – Patients on Drug Targin – metodo LRX (Longitudinal Prescription) 2012
   Google Scholar
• Clemens KE, Mikus G. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain. Expert Opin Pharmacother 2010;11:297-310
   PubMed Web of Science ®Google Scholar
• Dunlop W, Uhl R, Khan I, Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ 2012;15:564-75
   PubMedGoogle Scholar
• Mercadante S, Ferrera P, David F, Casuccio A. The use of high doses of oxycodone in an acute palliative care unit. Am J Hosp Palliat Care 2011;28:242-4
   PubMed Web of Science ®Google Scholar